Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05362474
Other study ID # 22-0187
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date July 1, 2022
Est. completion date June 20, 2023

Study information

Verified date April 2024
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date June 20, 2023
Est. primary completion date June 20, 2023
Accepts healthy volunteers No
Gender All
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - CKD stage 3 - urine albumin to creatinine ratio 200-5000 mg/g - blood pressure <140/90 mmHg - use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks - history of diabetes type 1 or 2 - BMI <40 kg/m2 - Stable antihypertensive regimen for at least one month prior to enrollment - Stable diabetes regimen for at least one month prior to enrollment - Sedentary or recreationally active (<2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements) - Able to provide consent Exclusion Criteria: - Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year - Uncontrolled hypertension - Factors judged to limit adherence to interventions (e.g. history of medication noncompliance, noncompliance with follow up visits, significant cognitive impairment, etc.) - Anticipated initiation of dialysis or kidney transplantation within 3 months - Current participation in another research study - Pregnancy or planning to become pregnant or currently breastfeeding - Allergy to aspirin - Severe hepatic impairment (Child-Pugh Class C) - History of major psychiatric disorder - Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction) - Current use of SGLT2 inhibitor - Current use of phenobarbital, rifampin or carbamazepine.

Study Design


Intervention

Drug:
Montelukast
10mg orally once a day

Locations

Country Name City State
United States University of Colorado Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Albuminuria at 3 months Change in 24-hour urine albumin excretion at 3 months Baseline, 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06006689 - Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis) Phase 2
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Not yet recruiting NCT06120569 - Evaluate the Role of Soleus Muscle Exercise in Glycaemic Control in Diabetic Kidney Disease Patients N/A
Completed NCT02545049 - Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Phase 3
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Active, not recruiting NCT06176599 - Clinical Study on the Treatment of Diabetic Kidney Disease With Shenxiao Yuning Decoction With Syndrome of Qi and Yin Deficiency and Blood Stasis N/A
Recruiting NCT03716401 - Prognostic Imaging Biomarkers for Diabetic Kidney Disease
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT01377688 - Personalized Diabetic Kidney Disease Risk Info to Initiate and Maintain Health Behavior Changes N/A
Active, not recruiting NCT05514548 - Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease Phase 2
Recruiting NCT05507892 - Renal Mechanism of SGLT2 Inhibition Phase 2
Not yet recruiting NCT06049550 - The Influence of the Thickening of Bowman's Capsule on the Clinical Prognosis of Patients With Diabetic Kidney Disease
Not yet recruiting NCT05514184 - Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease N/A
Active, not recruiting NCT04589351 - Kidney Fat in Type 2 Diabetes and the Effects of Ezetimibe Phase 3
Active, not recruiting NCT04531163 - Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy Phase 2/Phase 3
Active, not recruiting NCT03620773 - Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Phase 1/Phase 2
Suspended NCT01878045 - Mechanisms of Diabetic Kidney Disease in American Indians